Amgen's Phosphate Binder Loss May Be Genzyme's Gain
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen is shelving its own development of the phosphate binder AMG 223 for treatment of hyperphosphatemia in chronic kidney disease, after Phase II results disappointed